Kungase kulinganise ukuwohloka kwamalungu amadolo
Imiphumela yocwaningo eyabika ngo-July 2005 inkinga ye- Arthritis & Rheumatism isikisela ukuthi ukwelashwa nge-antixytic doxycycline kunganciphisa ukuqhubeka kwe- osteoarthritis . I-Doxycycline iyi-antibiotic yeklasi yezokwelapha okuthiwa i-tetracyclines.
Mayelana nesifundo se-Doxycycline ka-2005
Abacwaningi baqhathanisa ukusetshenziswa kwe-doxycycline endaweni ye-placebo, ngemuva kokubhalisa abesifazane abangaphezu kuka-400 abano- obesisifo samathambo njengabahlanganyeli bokutadisha.
Abahlanganyeli bezocwaningo babehlelwe ngamaqembu amabili, bethola ama-100 mg we-doxycycline kabili ngosuku noma i-placebo iminyaka engaba ngu-2.5. Abacwaningi bahlaziya umthelela we-doxycycline endaweni ehlangene yamadolo athintekile.
Ukulandela ukwelashwa kwezinyanga ezingu-16, imiphumela ibonise ukuthi ukulahlekelwa okuvamile kwesibalo esivumelanisiwe emadolweni ashintshiwe kwakungamaphesenti angama-40% phakathi kwabahlanganyeli abathatha i-doxycycline kunelabo abathatha i-placebo. Ekupheleni kwesikhathi seminyaka emibili nesigamu, ukulahlekelwa kwesibambisene okuhlangene kwaba yi-33% ngaphansi eqenjini elithatha i-doxycyline kuneqembu le-placebo. I-Doxycycline nayo ihlotshaniswa nokunyuka okubikwe kwesiguli emadolweni. Nokho, abacwaningi bavuma ukuthi izinga lobuhlungu lobukhulu laliphansi kumaqembu womabili.
Ucwaningo luka-2005 luyi-first study enkulu ye doxycycline njengendlela yokwelashwa kwe-osteoarthritis. Ngaleso sikhathi, kuthiwa izifundo eziningi kuzodingeka ukuze kuqinisekiswe imiphumela.
Amazwana Kusuka kuDkt. Zashin
Ngokuphathelene ne-doxycycline ne-osteoarthritis, isazi se-rheumatologist uScott Zashin, uM MD wathi, "Okokuqala, lokhu kuyisifundo esiyingqayizivele ngoba kwakuyisifundo esifushane eside esibheka imithi yokwehlisa nje ubuhlungu, kodwa nokuvimbela ukuqhubeka we-osteoarthritis of the knee.
Ngenkathi lolu cwaningo alubonanga ngokucacile ukuthi i-doxycycline yomlomo yayiphumelele ekunciphiseni ubuhlungu, bekukhona ubufakazi bokuthi kunokunyuka okuncane kwe-osteoarthritis (okungukuthi, ukulahleka okuncane kwe-cartilage) kuziguli ezilwa nemithi elwa namagciwane. Abalobi bakwenza kucacile ukuthi imithi yokulwa namagciwane yayizwakala ukuthi isebenze ngokusekelwe ezakhiweni zayo eziphikisayo , hhayi ngenxa yomphumela wayo wokulwa namagciwane. "
UDkt. Zashin waqhubeka wathi, "Ucwaningo luni lusho ukuthini iziguli ezine-osteoarthritis? Izinkinga zomtholampilo ezimbili ezibalulekile ezigulini nodokotela zifaka ukuthi ngabe imithi iyanciphisa ukungaxhunyiwe okuhlangene nokuthi ngabe isiguli singasidinga ukujoyina ngokuhlanganyela esikhathini esizayo. , kunzima ukutusa i-doxycyline yesikhathi eside ukuze uthole usizo lwezimpawu . Ngakolunye uhlangothi, kungenzeka ukuthi iziguli ezithatha imithi ye-antibiotic zingase zingabi nhlobo amathuba okudinga ukushintshwa ngokuhlanganyela esikhathini esizayo ngenxa yokwehla komonakalo ohlangene kwi-radiograph. Ngeshwa ukuthi uphendule lo mbuzo, kuzodingeka ucwaningo olude kakhulu. Ezinye imibuzo okufanele zicatshangelwe ukuthi ngabe iziguli zizodinga ukuhlala ezinqandeni zokulwa namagciwane kuze kube phakade ukusiza ukunciphisa umonakalo ohlanganyelwe kanye nokuvimbela ukushintshwa okuhlangene okulandelayo futhi yiziphi imiphumela emibi ezivela kulokhu kudala, umgomo wesikhathi.
Omunye umbuzo uwukuthi noma ukwelashwa kwezinyanga ezingu-30 nomuthi, ngokwalo, kunciphisa amathuba okuba ngokuhamba kwesikhathi, lezo ziguli ngeke zibe nempilo encane yokufuna ukuhlinzwa. Ngithemba, leli gumbi leziguli lingakwazi ukuqhubeka lifundiswa esikhathini esizayo ukusiza ukuphendula le mibuzo. "
Ukubuyekezwa kwe-Cochrane ka-2012 ka-Doxycycline ye-Osteoarthritis
Ngo-2012, ukubuyekezwa kwanyatheliswa ngokubuyekezwa kwe-cochrane kwe-doxycycline ye-osteoarthritis ekuqaleni eyanyatheliswa ngo-2009. Ukubuyekezwa kuhlolwe ubufakazi ezincwadini zezokwelapha eziye zahlola imiphumela ye-doxycycline ebuhlungu nasekusebenzeni ngokomzimba kuziguli ezine-osteoarthritis ye-hip noma idolo uma kuqhathaniswa kuya endaweni.
Kufundwa izifundo ezimbili kuphela ezibandakanya abantu abangu-663 futhi zifakiwe ekubuyekezweni. Ukubuyekezwa kwaphetha ngokuthi umphumela we-doxycycline ezimpawu zobuhlungu be-osteoarthritis awubalulekile emtholampilo. Abafundi abathintekayo balinganise ukuthuthukiswa kobuhlungu njengoba ku-1.9 ngesilinganiso se-0 (akukho ubuhlungu) kuya ku-10 (ubuhlungu obunzima) kuqhathaniswa nokuthuthukiswa kwamaphuzu angu-1.8 kwabaguli be-placebo ngemva kwezinyanga ezingu-18.
Imiphumela yokubuyekeza iphinde ikhombise ukuthi umphumela we-doxycycline ekusebenzeni ngokomzimba kwakungabalulekile ngokomtholampilo. Ukuthuthukiswa kokusebenza ngokomzimba kwakungama-1.4 okungafani no-1.2 amaphuzu ezingeni elingu-10 labahlanganyeli abathatha i-doxycycline ngokumelene ne-placebo, ngokulandelana.
Kubuye kwaphawula ekubuyekezeni ukuthi ama-20% wabathintekayo abathatha i-doxycycline babhekana nemiphumela emibi (yanoma yiluphi uhlobo) uma kuqhathaniswa no-15% walabo abathatha i-placebo. Ekugcineni, inzuzo ye-doxycycline ephathelene nokulahlekelwa kwendawo ehlangene eyayibikwa okokuqala ibhekwa njengento encane kanye nokubandakanyeka komtholampilo ekubukeni kweChrane.
> Imithombo:
> Imiphumela ye-Doxycycline ekuqhubekisweni kwe-Osteoarthritis: Imiphumela ye-Trial, i-Placebo-Controlled, Tri-Blind Trial. I-Brandt KD et al. I-arthritis ne-Rheumatology. July 2005.
> Doxycycline ye-Osteoarthritis ye-Knee noma i-Hip. da Costa BR et al. I-Cochrane Library. Novemba 2012.